Inactivation of the p16 tumor suppressor gene in adrenocortical tumors

被引:22
作者
Pilon, C
Pistorello, M
Moscon, A
Altavilla, G
Pagotto, U
Boscaro, M
Fallo, F
机构
[1] Univ Padua, Dept Med & Surg Sci, Div Endocrinol, I-35128 Padua, Italy
[2] Univ Padua, Dept Pathol, I-35128 Padua, Italy
关键词
D O I
10.1210/jc.84.8.2776
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mechanisms of adrenocortical tumorigenesis are still unknown. Evidence that the majority of adrenocortical tumors are monoclonal in origin suggests that a progressive accumulation of genetic aberrations, due to activation of protooncogenes and/or inactivation of tumor suppressor genes, leads to abnormal cell proliferation through a multistep process. Inactivation of the p16 tumor suppressor gene (p16(INK4A)), which encodes the cell cycle protein p16, was investigated in a series of 14 adrenocortical tumors. Using 11 polymorphic microsatellite markers spanning the short arm of chromosome 9, we demonstrated that three of seven adrenocortical carcinomas and one of seven adrenocortical adenomas had loss of heterozygosity (LOH) within chromosome 9p21, the region containing p16(INK4A). Immunohistochemistry showed the absence of p16 nuclear staining in all adrenocortical tumors with LOH within 9p21, and positive staining in all remaining tumors without LOH. In conclusion, LOH within 9p21 associated with lack of p16 expression occurs in a considerable proportion of adrenocortical malignant tumors, but is rare in adenomas. Inactivation of p16(INK4A) may contribute to the deregulation of cell proliferation in this neoplastic disease.
引用
收藏
页码:2776 / 2779
页数:4
相关论文
共 34 条
[1]  
[Anonymous], 1989, Molecular Cloning: A Laboratory Manual
[2]   Risk factors and long-term follow-up of adrenal incidentalomas [J].
Barzon, L ;
Scaroni, C ;
Sonino, N ;
Fallo, F ;
Paoletta, A ;
Boscaro, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :520-526
[3]  
Barzon L, 1997, ONCOLOGY, V54, P490
[4]   Incidentally discovered adrenal tumors: Endocrine scintigraphic correlates [J].
Barzon, L ;
Scaroni, C ;
Sonino, N ;
Fallo, F ;
Gregianin, M ;
Macri, C ;
Boscaro, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (01) :55-62
[5]  
BEUSCHLEIN F, 1994, CANCER RES, V54, P4927
[6]   FREQUENCY OF HOMOZYGOUS DELETION AT P16/CDKN2 IN PRIMARY HUMAN TUMORS [J].
CAIRNS, P ;
POLASCIK, TJ ;
EBY, Y ;
TOKINO, K ;
CALIFANO, J ;
MERLO, A ;
MAO, L ;
HERATH, J ;
JENKINS, R ;
WESTRA, W ;
RUTTER, JL ;
BUCKLER, A ;
GABRIELSON, E ;
TOCKMAN, M ;
CHO, KR ;
HEDRICK, L ;
BOVA, GS ;
ISAACS, W ;
KOCH, W ;
SCHWAB, D ;
SIDRANSKY, D .
NATURE GENETICS, 1995, 11 (02) :210-212
[7]  
Farrell WE, 1997, CANCER RES, V57, P2703
[8]  
FLACK MR, 1996, CANC MED, P1563
[9]  
GERADTS J, 1995, CANCER RES, V55, P6006
[10]   RECENT ADVANCES IN THE PATHOGENESIS OF ADRENOCORTICAL TUMORS [J].
GICQUEL, C ;
BERTAGNA, X ;
LEBOUC, Y .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 133 (02) :133-144